[Clinical analysis of juvenile ovary granulose cell tumor].
OBJECTIVE
To explore clinicopathological features and prognosis of juvenile granulosa cell tumor (JGCT).


METHODS
Patients were divided into JGCT group (n = 10) and the adult granulosa cell tumor (AGCT) group (n = 10). The tumor samples were examined by HE and immunohistochemical methods.


RESULTS
Age of JGCT group ranged from 7 - 31 years (average 20.5 years); 90% occurred before 30 years old. Diameter of the tumors ranged from 5.5 cm to 15.0 cm, average 9.8 cm. Characteristic features included nodular arrangement, irregular formation of follicles containing mucin and luteinization, atypical hyperplasia of cells and high mitotic activity. Nuclei grooved and Call-Exner bodies were absent or rare. Survival rate was 90% in 5 years. Age of AGCT group ranged from 14 - 74 years (average 45.1 years); AGCT occurred mostly in over 40 years old. Atypical hyperplasia of cell, mitotic activity and luteinization were absent or rare. Nuclei grooved and call-Exner bodies were common. Survival rate was 100% in 5 years. Immunohistochemical staining were positive for p53 at 70%, PCNA at 90% in 10 cases of JGCT and p53 at 10%, PCNA at 20% in 10 cases of AGCT (P < 0.05 between two groups).


CONCLUSIONS
JGCT differs in clinicopathologic feature from the AGCT. It has higher mitotic activity and nuclear atypicality as well as the expression of PCNA and p53. Prognosis of JGCT is worse than AGCT.
Huang
Jiang-ning
JN
Department of Obstetrics and Gynecology, People's Hospital of Shajing Shenzhen, Shenzhen 518104, China. hjnxx001@sina.com
Liu
Yi-zhi
YZ
Zhang
Xin-min
XM
D000293:Adolescent; D000328:Adult; D000368:Aged; D000818:Animals; D002648:Child; D003937:Diagnosis, Differential; D005260:Female; D005500:Follow-Up Studies; D006106:Granulosa Cell Tumor / Q000378:metabolism / Q000401:mortality / Q000473:pathology*; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000378:metabolism / Q000401:mortality / Q000473:pathology*; D011379:Prognosis; D018809:Proliferating Cell Nuclear Antigen / Q000096:biosynthesis*; D012189:Retrospective Studies; D016019:Survival Analysis; D015996:Survival Rate; D016159:Tumor Suppressor Protein p53 / Q000096:biosynthesis*
D018809:Proliferating Cell Nuclear Antigen; D016159:Tumor Suppressor Protein p53